Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Parvus Therapeutics has just scored a discovery deal with Genentech on autoimmune diseases, putting them in alliance with one of the most sought-after partners in the business.
We don’t know what the upfront is — and typically Genentech isn’t known for splurging big on discovery bets — but the whole deal, biobucks included, weighs in at a prospective $800 million.
Whatever they’re anteing up, Genentech will now hop on the Burlingame, CA-based biotech’s Navacim platform, which converts effector cells into regulatory T cells, Tregs, that in turn whip up immune regulator cells to mob the inflammatory cells that trigger autoimmune diseases like rheumatoid arthritis and multiple sclerosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
